KRYS
Krystal Biotech, Inc.
One of the first gene-therapy companies to reach patients, it makes VYJUVEK, a gel applied to open wounds that treats dystrophic epidermolysis bullosa (DEB), a rare disease where skin blisters like butterfly wings. Founded in 2016 by husband-and-wife team Krish and Suma Krishnan, who self-funded its start, the company named itself "Krystal" for the clarity and precision it wanted in gene therapy.
CUSIP: 501147102HealthcareUS2 holders
Total Value
$24.77M
Total Shares
66.6K
Net Share Change
+8.2K
Activity
2 buying
Investor
Value
Shares
Weight
Change
